Shares of Exelixis (EXEL -13%) were hammered today after the biotech firm announced plans to hold back-to-back public offerings. It plans to offer, subject to market conditions, 20M common shares and an aggregate $225M of convertible senior subordinated notes due in 2019.
Sent to 4,901 people who get email alerts on EXEL.
Get email alerts on EXEL »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.